Antibody Sequencing Service
Workflow of de novo Antibody Protein Sequencing
It is required to obtain the protein sequence of a monoclonal antibody (mAb) for development of novel biotherapeutics. The need to extensively characterize mAbs at the molecular level presents a unique challenge to drug developers and manufacturers.
PEAKS AB Service provides the answer to this.
- Design and perform LC-MS/MS analysis (0.2mg of mAb protein)
- de novo protein sequencing
- Works for all antibody isotypes and species
- Quantify PTMs and sequence variants
- Guarantee two-week turn-around and service quality
BSI has developed the proprietary de novo antibody sequencing technology, based on our PEAKS AB Software, to sequence antibodies 1,2. The Antibody Sequencing Service consists of full length heavy and light-chain antibody sequencing for all species, isotypes and allotypes. Numerous successful cases from our antibody protein sequencing service have confirmed 100% accuracy and 100% coverage. Satisfaction is guaranteed to meet our customers’ needs.
100% Sequence Coverage
Our Antibody Sequencing Service guarantees each amino acid is typically mapped with more than 20 peptides. The peptide mapping in the left is obtained using our PEAKS AB Software at 0.1% of FDR at peptide-spectrum level. Each bar under the sequence denotes a peptide identified from the MS/MS data and the color represents a specified enzyme used for sample digestion.
100% Sequence Accuracy
The Antibody Protein Sequencing Service carries out quality control at the amino acid level based on the de novo sequencing result. Direct fragment ion evidences from MS/MS data are required for each amino acid in the assembled protein sequences.
Comprehensive Modification Analysis
The Antibody Protein Sequencing Service provides qualitative and quantitative analysis for post-translational modifications (PTMs) and sequence variants. The screenshot illustrates a PTM analysis result using our PEAKS AB Software.
Confident Leucine & Isoleucine Differentiation
Leucine (Leu) and Isoleucine (Ile) residues are generally considered to be indistinguishable by MS. Due to this ambiguity, it is difficult to differentiate between the two residues and this can impose serious consequences on the overall performance of the antibody’s specificity and affinity. In our Antibody Sequencing Service, we use an integrated strategy that combines 1) w-ion detection in EThcD, 2) enzyme cleavage preference, and 3) homology statistics for unambiguous discrimination of Leu/Ile residues.
- Shan, B. and Xin, L. Integrating de novo Sequencing and Database Search for Monoclonal Antibody Sequencing. J Biomol Tech. 24(Suppl). S62–S63. 1/5/2013.
- Tran, N.H. et al. Complete De Novo Assembly of Monoclonal Antibody Sequences. Sci Rep. 6:31730. 26/08/2016.
- Johnson, R. S. et al. Novel Fragmentation Process of Peptides by Collision-Induced Decomposition in a Tandem Mass Spectrometer: Differentiation of Leucine and Isoleucine. Anal Chem. 1987 Nov 1;59(21):2621-5.
- Xiao, Y. et al. Distinguishing between Leucine and Isoleucine by Integrated LC-MS Analysis using an Orbitrap Fusion Mass Spectrometer. Anal Chem. 2016 Nov 1;88(21):10757-10766.
- Zhokhov, S. et al. An EThcD-Based Method for Discrimination of Leucine and Isoleucine Residues in Tryptic Peptides. J Am Soc Mass Spectrom. 2017 Aug;28(8):1600-1611.